je.st
news
Onglyza (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating ...
2013-09-02 10:10:35| Biotech - Topix.net
Onglyza Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial AstraZeneca and Bristol-Myers Squibb Company today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular ... (more)
Tags: primary
safety
demonstrating
achieves
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||